New Zenith immuno-oncology trial with Keytruda

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

New Zenith immuno-oncology trial with Keytruda

posted on Oct 25, 2019 09:29AM

In case you missed it in the slide deck.

New Phase 1b/2 immuno-oncology trial has been initiated by UCSF to test ZEN-3694 in combo with Keytruda and enzalutamide for AR independent mCRPC and other cancers. Key is to restore sensitivity to immune checkpoint PD-1 and PD-L1 antibody therapy.